Once associated with counterculture, psychedelics are now being studied — and monetized — as potential tools for behavioral healthcare

getty

Psychedelics are having a flashback. This one comes with investors. And though researchers have been intrigued by the therapeutic potential of psychedelic medicine for decades, this time the mood feels different: restrictions are loosening, investors are circling and the wellness world is ready to pounce.

Once associated with rave culture and adventurous experimentation, psychedelics are now being recast as the next breakthrough in behavioral healthcare. That may be true. It may also be the next hype cycle. What happens when promising medicine meets markets hungry for their next obsession?

Recent trading activity offers one clue. Shares of biotech firms and companies focused on psychedelic-assisted therapy rose after analysts welcomed an executive order from Donald Trump earlier this month aimed at accelerating research into certain psychedelic compounds. In other words, before many treatments have reached broad mainstream adoption, investor enthusiasm is already showing up.

The psychedelic story has always moved in cycles: curiosity, exuberance, backlash, rediscovery. Clinicians at Harvard Medical School have noted that psychedelics once moved from early scientific excitement to public outcry during the late 1960s, as fears about safety and counterculture excess overtook initial optimism. The Nixon administration put a halt to the field’s early momentum, freezing promising research for decades. Today, the pendulum is swinging again — this time toward therapeutic promise, clinical legitimacy and commercial opportunity.

Early clinical findings in areas such as depression, PTSD and other mental illnesses have generated legitimate excitement. But many studies remain relatively small, tightly controlled or difficult to replicate in broader real-world settings. As with many emerging therapies, efficacy in research environments does not automatically guarantee scalable outcomes in routine care.

“Patients are seeking remedies with effects that are simultaneously rapid, durable and effective,” says David Marcovitz, M.D., associate professor of psychiatry and behavioral sciences at Vanderbilt Health and co-founder of Valence, an integrated program for business leaders and their families. “We are seeing that the demand for such medicines can lead the market to try to cater to those desires.”

Momentum is building. Johnson & Johnson opened the commercial door with FDA approval of Spravato, an intranasal form of the powerful dissociative ketamine approved for treatment delivered in controlled, clinical settings. Startups, clinics and investors have rushed in behind it.

The demand is real. Millions remain underserved by traditional mental health systems. But one regulated success does not guarantee a scalable model. The real question is whether psychedelic medicine can be delivered safely, affordably and at scale — or whether the market is moving faster than the infrastructure required to support it.

Unlike conventional medications, many psychedelic therapies may require hours of clinician time, patient preparation, monitored administration and post-treatment support. That creates a labor-intensive model in a system already short on behavioral health professionals. Investors may see a growth category. Operators see staffing, liability, reimbursement and throughput constraints.

The biggest psychedelic trip may be the bill. Spravato has shown that once a treatment earns FDA approval and insurance coverage, adoption can accelerate. But many ketamine treatments still cost patients $2,400 to $4,800 for an initial series, while some MDMA-assisted therapy estimates exceed $11,000 per course. If insurers hesitate, mainstream medicine could become luxury medicine. Psychedelics face the same challenge as much of U.S. healthcare: promising innovation trapped inside expensive delivery systems.

Even if insurance coverage expands, access may still be limited by workforce realities. Many psychedelic treatment models depend on psychiatrists, psychologists, therapists, nurses or specially trained facilitators — professionals already in short supply. Health Resources and Services Administration has identified thousands of Mental Health Professional Shortage Areas across the country, affecting tens of millions of Americans. HRSA currently designates more than 6,000 mental health shortage areas nationwide. In practical terms, therapies requiring hours of supervised clinician time may struggle to scale precisely where mental health demand is greatest.

Affluent patients may also become the earliest test market. When conventional systems move slowly, high-net-worth consumers often pay out of pocket for faster access, premium experiences and treatments not yet fully integrated into mainstream care. That can create advantages — but also added exposure to uneven standards, aggressive marketing and clinics operating ahead of clear regulatory guardrails. In emerging healthcare markets, wealth can buy convenience. In healthcare, being first is not always the same as being safest.

In healthcare, curiosity is useful. Due diligence is essential. Ask whether a treatment is FDA-approved or experimental, who is supervising care, what screening protocols are used, how emergencies are handled and what total costs may be. Consumers should also understand whether therapy, medication or both are included — and whether claims are supported by published evidence.

Healthcare bubbles rarely burst all at once — they sort themselves. And market repricing is already happening. The likely survivors will be companies with real data, disciplined compliance and practical paths to scale. Those relying mainly on cultural momentum may discover that investor enthusiasm is easier to raise than clinical adoption.

Psychedelic medicine may contain two truths at once: real therapeutic promise and real speculative excess. The winners will be those that can prove one without depending on the other.